XGEN Venture led a €83.5m Series A round in NanoPhoria Bioscience.

XGEN Venture, an Italian alternative investment fund manage, led a €83.5m Series A round in NanoPhoria Bioscience, a pre-clinical stage biotech company, with a participation from Sofinnova Partners, CDP Venture Capital and Panakès Partners. “NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseases which is why we are excited to invest in this company,” Henrijette Richter, Sofinnova Partners Managing Partner.